Clinical trials: Advanced Solid Malignancy
Advanced Solid Tumor, Advanced Solid Malignancies
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.
- Trial name
- NCT05159700
- Testing
- PRJ1-3024
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Bladder Cancer, Urothelial Carcinoma
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- DUET-UC-NK (NCT07492628)
- Testing
- EB-DT-NK-UC101, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Neoplasm
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.
- Trial name
- NCT02514603
- Testing
- Prexasertib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
- Conditions
- Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma
- Trial name
- INSPIRE (NCT02644369)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Advanced Solid Tumors
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04169672
- Testing
- Surufatinib, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Hutchison Medipharma Limited
Lung Cancer, Hepatocellular Carcinoma
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
- Conditions
- Lung Cancer, Hepatocellular Carcinoma, Solid Tumor
- Trial name
- NCT04952272
- Testing
- CpG-ODN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
This study is a Phase II, two-cohort, multicenter, two-stage clinical trial. It plans to enroll 72 subjects with solid tumors who discontinued prior ICI therapy due to irAE.
- Trial name
- NCT07313202
- Testing
- Ivarmacitinib
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Advanced Solid Tumor
TR64 in Patients With Advanced Solid Tumors
This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid…
- Trial name
- NCT05649345
- Testing
- TR64
- Where
- 2 sites in China
- Volunteers
- 19 people
- Sponsor
- Tarapeutics Science Inc.
Ovarian Neoplasms, Peritoneal Neoplasms
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT05194072
- Testing
- Felmetatug Vedotin, Pembrolizumab
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 250 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Solid Tumors, Lymphomas
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1.
- Trial name
- NCT00947739
- Testing
- Camptothecin-20-O-Propionate Hydrate (CZ48)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- New Mexico Cancer Research Alliance
Polyphenols, Cancer Vaccine
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
This project intends to carry out phase I clinical studies on the basis of the previous work, initially exploring the possible effective dose, evaluating its safety and tolerability, with a view to achieving long-term control of…
- Conditions
- Polyphenols, Cancer Vaccine, Advanced Solid Tumor
- Trial name
- NCT06878612
- Testing
- Polyphenol whole tumor cell vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xingchen Peng
Solid Tumor
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors.
- Trial name
- NCT05266612
- Testing
- VG2025, Nivolumab Injection [Opdivo]
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Virogin Biotech Canada Ltd
Advanced Solid Tumor
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment…
- Trial name
- NCT06404281
- Testing
- γδ T-PD-1 Ab cells
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital
Solid Tumor
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors
- Trial name
- NCT06258330
- Testing
- AM003
- Where
- 5 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Aummune Ltd.
Solid Tumors, Adult
Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours
By controlling the patient's blood sugar, small doses of chemotherapy are used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, and…
- Trial name
- NCT06404528
- Testing
- Blood glucose stress combined with low-dose chemotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuxi People's Hospital
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02712905
- Testing
- INCB059872, all-trans retinoic acid (ATRA), azacitidine
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 116 people
- Sponsor
- Incyte Corporation
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Cancer
Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System
This is an open-label, three-parallel group pharmacokinetic study. Patients with advanced solid tumors will be assigned to one of three groups to receive I.V. doses of eribulin (E7389).
- Trial name
- NCT00706095
- Testing
- E7389
- Where
- 2 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- Eisai Inc.
Neoplasms
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the…
- Trial name
- NCT03521037
- Testing
- Rucaparib camsylate
- Where
- 6 sites in Poland, Slovakia and 1 more
- Volunteers
- 16 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.